APA (7th ed.) Citation

Voss, M. H., Chen, D., Reising, A., Marker, M., Shi, J., Xu, J., . . . Motzer, R. J. (2019). PTEN Expression, Not Mutation Status in TSC1, TSC2 , or mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clinical cancer research, 25(2), 506-514. https://doi.org/10.1158/1078-0432.CCR-18-1833

Chicago Style (17th ed.) Citation

Voss, Martin H., et al. "PTEN Expression, Not Mutation Status in TSC1, TSC2 , or MTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial." Clinical Cancer Research 25, no. 2 (2019): 506-514. https://doi.org/10.1158/1078-0432.CCR-18-1833.

MLA (9th ed.) Citation

Voss, Martin H., et al. "PTEN Expression, Not Mutation Status in TSC1, TSC2 , or MTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial." Clinical Cancer Research, vol. 25, no. 2, 2019, pp. 506-514, https://doi.org/10.1158/1078-0432.CCR-18-1833.